1887

Abstract

The PorA protein is a potential candidate as a vaccine component against meningococcal disease. However, this protein experiences antigenic variation and is subject to phase variations to evade immune selective pressure. In this study, the mechanisms responsible for altered expression of the PorA protein were analysed in 50 non-subtypable strains isolated from patients with meningococcal disease in Spain. The gene was amplified from 47 of the 50 strains. The majority of isolates were not recognized by the subtyping panel, as a result of non-synonymous base changes in the variable regions of the gene. Two of these strains revealed a premature stop codon before the variable region VR1 of PorA due to a single base-pair substitution at position 109 of the coding region. Another two presented a homopolymeric tract of eight adenine residues in the coding region, producing a DNA strand-slippage mechanism and PorA phase variation.

Loading

Article metrics loading...

/content/journal/jmm/10.1099/jmm.0.05517-0
2004-06-01
2019-11-13
Loading full text...

Full text loading...

/deliver/fulltext/jmm/53/6/JM530608.html?itemId=/content/journal/jmm/10.1099/jmm.0.05517-0&mimeType=html&fmt=ahah

References

  1. Arhin, F. F., Moreau, F., Coulton, J. W. & Mills, E. L. ( 1997;). Subtyping of Neisseria meningitidis strains isolated in Quebec, Canada: correlation between deduced amino acid sequences and serosubtyping techniques. Can J Microbiol 43, 234–238.[CrossRef]
    [Google Scholar]
  2. Cartwright, K., Morris, R., Rumke, H., Fox, A., Borrow, R., Begg, N., Richmond, P. & Poolman, J. ( 1999;). Immunogenicity in UK infants of a novel meningococcal vesicle vaccine containing multiple class 1 (PorA) outer membrane proteins. Vaccine 17, 2612–2619.[CrossRef]
    [Google Scholar]
  3. Crowe, B. A., Wall, R. A., Kusecek, B. & 7 other authors ( 1989;). Clonal and variable properties of Neisseria meningitidis isolated from cases and carriers during and after an epidemic in The Gambia, West Africa. J Infect Dis 159, 686–700.[CrossRef]
    [Google Scholar]
  4. Deghmane, A. E., Giorgini, D., Larribe, M., Alonso, J. M. & Taha, M. K. ( 2002;). Down-regulation of pili and capsule of Neisseria meningitidis upon contact with epithelial cells is mediated by CrgA regulatory protein. Mol Microbiol 43, 1555–1564.[CrossRef]
    [Google Scholar]
  5. de Kleijn, E. D., de Groot, R., Labadie, J. and 9 other authors ( 2000;). Immunogenicity and safety of a hexavalent meningococcal outer-membrane-vesicle vaccine in children of 2–3 and 7–8 years of age. Vaccine 18, 1456–1466.[CrossRef]
    [Google Scholar]
  6. Feavers, I. M. & Maiden, M. C. J. ( 1998;). A gonococcal porA pseudogene: implications for understanding the evolution and pathogenicity of Neisseria gonorrhoeae. Mol Microbiol 30, 647–656.[CrossRef]
    [Google Scholar]
  7. Guiver, M. & Borrow, R. ( 2001;). PCR diagnosis. In Meningococcal Disease: Methods and Protocols, pp. 23–39. Edited by A. J. Pollard & M. C. J. Maiden. Totowa, NJ: Humana Press.
  8. Hopman, C. T. P., Dankert, J. & van Putten, J. P. M. ( 1994;). Variable expression of the class 1 protein of Neisseria meningitidis. In Pathology and Immunobiology of Neisseriaceae, pp. 513–517. Edited by C. J. Conde-Glez, S. Morse, P. Rice, F. Sparling & E. Calderon. Cuernavaca, Mexico: Instituto Nacional de Salud Pública.
  9. Longworth, E., Borrow, R., Goldblatt, D., Balmer, P., Dawson, M., Andrews, N., Miller, E. & Cartwright, K. ( 2002;). Avidity maturation following vaccination with a meningococcal recombinant hexavalent PorA OMV vaccine in UK infants. Vaccine 20, 2592–2596.[CrossRef]
    [Google Scholar]
  10. Martin, S., Sadler, F., Borrow, R., Dawson, M., Fox, A. & Cartwright, K. ( 2001;). IgG antibody subclass responses determined by immunoblot in infants’ sera following vaccination with a meningococcal recombinant hexavalent PorA OMV vaccine. Vaccine 14, 4404–4408.
    [Google Scholar]
  11. Newcombe, J., Cartwright, K., Dyer, S. & McFadden, J. ( 1998;). Naturally occurring insertional inactivation of the porA gene of Neisseria meningitidis by integration of IS1301. Mol Microbiol 30, 453–454.[CrossRef]
    [Google Scholar]
  12. Peeters, C. C., Rumke, H. C., Sundermann, L. C., Rouppe van der Voort, E. M., Meulenbelt, J., Schuller, M., Kuipers, A. J., van de Ley, P. & Poolman, J. T. ( 1996;). Phase I clinical trial with a hexavalent PorA containing meningococcal outer membrane vesicle vaccine. Vaccine 14, 1009–1015.[CrossRef]
    [Google Scholar]
  13. Rosenqvist, E., Hoiby, E. A., Wedege, E., Bryn, K., Kolberg, J., Klem, A., Ronnild, E., Bjune, G. & Nokleby, H. ( 1995;). Human antibody response to meningococcal outer membrane antigens after three doses of the Norwegian group B meningococcal vaccine. Infect Immun 63, 4642–4652.
    [Google Scholar]
  14. Sacchi, C. T., Whitney, A. M., Popovic, T. & 7 other authors ( 2000;). Diversity and prevalence of PorA types in Neisseria meningitidis serogroup B in the United States 1992–1998. J Infect Dis 182, 1169–1176.[CrossRef]
    [Google Scholar]
  15. Saukkonen, K., Abdillahi, H., Poolman, J. T. & Leinonen, M. ( 1987;). Protective efficacy of monoclonal antibodies to class 1 and class 3 outer membrane proteins of Neisseria meningitidis B : 15 : P1.16 in infant rat infection model: new prospects for vaccine development. Microb Pathog 3, 261–267.[CrossRef]
    [Google Scholar]
  16. Saukkonen, K., Leinonen, M., Abdillahi, H. & Poolman, J. T. ( 1989;). Comparative evaluation of potential components for group B meningococcal vaccine by passive protection in the infant rat and in vitro bactericidal assay. Vaccine 7, 325–328.[CrossRef]
    [Google Scholar]
  17. Sawaya, R., Arhin, F. F., Moreau, F., Coulton, J. W. & Mills, E. L. ( 1999;). Mutational analysis of the promoter region of the porA gene of Neisseria meningitidis. Gene 233, 49–57.[CrossRef]
    [Google Scholar]
  18. Urwin, R. ( 2001;). Nucleotide sequencing of antigen genes of Neisseria meningitidis. In Meningococcal Disease: Methods and Protocols, pp. 157–172. Edited by A. J. Pollard & M. C. J. Maiden. Totowa, NJ: Humana Press.
  19. van der Ende, A., Hopman, C. T. P., Zaat, S., Oude Essink, B. B., Berkhout, B. & Dankert, J. ( 1995;). Variable expression of class 1 outer membrane protein in Neisseria meningitidis is caused by variation in the spacing between the −10 and −35 regions of the promoter. J Bacteriol 177, 2475–2480.
    [Google Scholar]
  20. van der Ende, A., Hopman, C. T. P. & Dankert, J. ( 1999;). Deletion of porA by recombination between clusters of repetitive extragenic palindromic sequences in Neisseria meningitidis. Infect Immun 67, 2928–2934.
    [Google Scholar]
  21. van der Ende, A., Hopman, C. T. P. & Dankert, J. ( 2000;). Multiple mechanisms of phase variation of PorA in Neisseria meningitidis. Infect Immun 68, 6685–6690.[CrossRef]
    [Google Scholar]
  22. van der Ende, A., Hopman, C. T. P., Keijzers, W. C. M., Spanjaard, L., Lodder, E. B., van Keulen, P. H. J. & Dankert, J. ( 2003;). Outbreak of meningococcal disease caused by PorA-deficient meningococci. J Infect Dis 187, 869–871.[CrossRef]
    [Google Scholar]
  23. van der Voort, E. R., van Dijken, H., Kuipers, B., van der Biezen, J., van der Ley, P., Meylis, J., Claassen, I. & Poolman, J. ( 1997;). Human B- and T-cell responses after immunization with a hexavalent PorA meningococcal outer membrane vesicle vaccine. Infect Immun 65, 5184–5190.
    [Google Scholar]
  24. Vázquez, J. A., Marcos, C. & Berrón, S. ( 1994;). Sero/subtyping of Neisseria meningitidis isolated from patients in Spain. Epidemiol Infect 113, 267–274.[CrossRef]
    [Google Scholar]
http://instance.metastore.ingenta.com/content/journal/jmm/10.1099/jmm.0.05517-0
Loading
/content/journal/jmm/10.1099/jmm.0.05517-0
Loading

Data & Media loading...

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error